Study S000332

Multicentre Randomized Double Blind, Crossover, Placebo Controlled Clinical Trial to Evaluate the Effect of Liraglutide on Lung Function in Patients With Type 2 Diabetes Mellitus (LIRALUNG Study)

ClinicalTrials.gov record Study Protocol and Statistical Analysis Plan (PDF)

Registration

Registration: NCT02889510
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE3
Masking: DOUBLE
Status: COMPLETED
Enrollment: 76
Start: 2016-10-04
Primary completion: 2019-11-18
Lead sponsor: Lecube, Albert, M.D.
Conditions: Type 2 Diabetes
Interventions: DRUG:liraglutide; DRUG:placebo
Results posted: TRUE
Individual participant data sharing: NO

Registered primary outcomes

Changes From Baseline on Measurements of Respiratory Function Defined by Forced Expiratory Volume in 1 Second (FEV1) [7 weeks]

Linked records (2)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0009387	Liraglutide Improves Forced Vital Capacity in Individuals With Type 2 Diabetes: Data From the Randomized Crossover LIRALUNG Study. López-Cano C, Diabetes	2022	Randomized trial	PMID 34737187 DOI	cites ClinicalTrials.gov:NCT02889510; registry reference DERIVED:34737187
R0027773	Glucagon-like peptide-1(7-36) amide stimulates surfactant secretion in human type II pneumocytes. Vara E, American journal of respiratory and critical care medicine	2001	Other	PMID 11282754 DOI	registry reference BACKGROUND:11282754